Smith & Nephew (SNN) Revenue & Revenue Breakdown
Smith & Nephew Revenue Highlights
Latest Revenue (Y)
$5.55B
Latest Revenue (Q)
$2.79B
Main Segment (Y)
Orthopaedics, Sports Medicine and ENT and Advanced Wound Management
Main Geography (Y)
United States of America
Smith & Nephew Revenue by Period
Smith & Nephew Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $5.55B | 6.40% |
| 2022-12-31 | $5.21B | 0.06% |
| 2021-12-31 | $5.21B | 14.30% |
| 2020-12-31 | $4.56B | -11.25% |
| 2019-12-31 | $5.14B | 4.77% |
| 2018-12-31 | $4.90B | 2.92% |
| 2017-12-31 | $4.76B | 2.06% |
| 2016-12-31 | $4.67B | 0.76% |
| 2015-12-31 | $4.63B | 0.37% |
| 2014-12-31 | $4.62B | 6.11% |
| 2013-12-31 | $4.35B | 5.17% |
| 2012-12-31 | $4.14B | -3.11% |
| 2011-12-31 | $4.27B | 7.77% |
| 2010-12-31 | $3.96B | 5.04% |
| 2009-12-31 | $3.77B | -0.76% |
| 2008-12-31 | $3.80B | 12.82% |
| 2007-12-31 | $3.37B | 21.23% |
| 2006-12-31 | $2.78B | 8.89% |
| 2005-12-31 | $2.55B | 6.57% |
| 2004-12-31 | $2.39B | 13.75% |
| 2003-12-31 | $2.11B | 17.76% |
| 2002-12-31 | $1.79B | 13.49% |
| 2001-12-31 | $1.58B | -7.06% |
| 2000-12-31 | $1.69B | -6.45% |
| 1999-12-31 | $1.81B | 3.61% |
| 1998-12-31 | $1.75B | 0.92% |
| 1997-12-31 | $1.73B | -5.37% |
| 1996-12-31 | $1.83B | 15.46% |
| 1995-12-31 | $1.59B | 5.16% |
| 1994-12-31 | $1.51B | 7.46% |
| 1993-12-31 | $1.40B | - |
Smith & Nephew generated $5.55B in revenue during NA 2023, up 6.40% compared to the previous quarter, and up 113.15% compared to the same period a year ago.
Smith & Nephew Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.79B | 2.14% |
| 2023-07-01 | $2.73B | 100.00% |
| 2023-04-01 | $1.37B | -50.16% |
| 2022-12-31 | $2.74B | 109.79% |
| 2022-09-30 | $1.31B | -49.71% |
| 2022-07-02 | $2.60B | 100.00% |
| 2022-04-02 | $1.30B | -50.71% |
| 2021-12-31 | $2.64B | 101.86% |
| 2021-09-30 | $1.31B | -49.73% |
| 2021-07-03 | $2.60B | 100.00% |
| 2021-04-03 | $1.30B | -47.60% |
| 2020-12-31 | $2.48B | 96.42% |
| 2020-09-30 | $1.26B | -37.96% |
| 2020-06-27 | $2.04B | 100.00% |
| 2020-03-27 | $1.02B | -62.16% |
| 2019-12-31 | $2.69B | 102.69% |
| 2019-09-30 | $1.33B | -46.62% |
| 2019-06-29 | $2.48B | 100.00% |
| 2019-03-29 | $1.24B | -49.57% |
| 2018-12-31 | $2.46B | 100.00% |
| 2018-09-30 | $1.23B | -49.51% |
| 2018-06-30 | $2.44B | 100.00% |
| 2018-03-31 | $1.22B | -49.77% |
| 2017-12-31 | $2.43B | 100.00% |
| 2017-09-30 | $1.21B | -48.01% |
| 2017-07-01 | $2.34B | 100.00% |
| 2017-04-01 | $1.17B | -50.11% |
| 2016-12-31 | $2.34B | 100.00% |
| 2016-09-30 | $1.17B | -49.72% |
| 2016-07-02 | $2.33B | 100.00% |
| 2016-04-02 | $1.16B | -50.72% |
| 2015-12-31 | $2.36B | 3.96% |
| 2015-06-27 | $2.27B | -5.21% |
| 2014-12-31 | $2.40B | 108.80% |
| 2014-09-30 | $1.15B | -48.29% |
| 2014-06-28 | $2.22B | 106.90% |
| 2014-03-31 | $1.07B | -51.27% |
| 2013-12-31 | $2.20B | 114.41% |
| 2013-09-30 | $1.03B | -52.21% |
| 2013-06-29 | $2.15B | 99.91% |
| 2013-03-31 | $1.07B | -0.19% |
| 2012-12-31 | $1.08B | 13.13% |
| 2012-09-30 | $952.00M | -7.48% |
| 2012-06-30 | $1.03B | -4.63% |
| 2012-03-31 | $1.08B | -2.44% |
| 2011-12-31 | $1.11B | 7.17% |
| 2011-09-30 | $1.03B | -4.18% |
| 2011-06-30 | $1.08B | 2.09% |
| 2011-03-31 | $1.05B | -1.12% |
| 2010-12-31 | $1.07B | 13.39% |
| 2010-09-30 | $941.00M | -1.88% |
| 2010-06-30 | $959.00M | -3.62% |
| 2010-03-31 | $995.00M | -6.66% |
| 2009-12-31 | $1.07B | 16.50% |
| 2009-09-30 | $915.00M | -1.19% |
| 2009-06-30 | $926.00M | 7.05% |
| 2009-03-31 | $865.00M | -9.90% |
| 2008-12-31 | $960.00M | 3.23% |
| 2008-09-30 | $930.00M | -7.00% |
| 2008-06-30 | $1.00B | 9.77% |
| 2008-03-31 | $911.00M | -5.79% |
| 2007-12-31 | $967.00M | 14.44% |
| 2007-09-30 | $845.00M | 3.94% |
| 2007-06-30 | $813.00M | 9.27% |
| 2007-03-31 | $744.00M | -3.50% |
| 2006-12-31 | $771.00M | 13.55% |
| 2006-09-30 | $679.00M | -1.02% |
| 2006-06-30 | $686.00M | 6.69% |
| 2006-03-31 | $643.00M | -262.53% |
| 2005-12-31 | $-395.62M | -165.76% |
| 2005-09-30 | $601.64M | -4.15% |
| 2005-06-30 | $627.65M | -0.05% |
| 2005-03-31 | $628.00M | -11.08% |
| 2004-12-31 | $706.27M | 26.90% |
| 2004-09-30 | $556.56M | -0.33% |
| 2004-06-30 | $558.40M | 0.33% |
| 2004-03-31 | $556.59M | -12.49% |
| 2003-12-31 | $636.03M | 23.76% |
| 2003-09-30 | $513.90M | -0.51% |
| 2003-06-30 | $516.54M | 17.69% |
| 2003-03-31 | $438.89M | 41.94% |
| 2002-12-31 | $309.21M | -38.57% |
| 2002-09-30 | $503.34M | 25.42% |
| 2002-06-30 | $401.32M | -11.65% |
| 2002-03-31 | $454.24M | 36.02% |
| 2001-12-31 | $333.94M | -10.42% |
| 2001-09-30 | $372.78M | -3.90% |
| 2001-06-30 | $387.89M | -0.09% |
| 2001-03-31 | $388.23M | -40.19% |
| 2000-12-31 | $649.08M | 113.10% |
| 2000-09-30 | $304.59M | - |
Smith & Nephew generated $2.79B in revenue during Q4 2023, up 2.14% compared to the previous quarter, and up 107.41% compared to the same period a year ago.
Smith & Nephew Revenue Breakdown
Smith & Nephew Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Advanced Wound Management | $1.61B | $1.51B | $1.50B | $1.31B | $1.38B |
| Orthopaedics, Sports Medicine and Ear Nose and Throat | $3.94B | $3.70B | $3.72B | - | - |
| Orthopaedics, Sports Medicine and ENT and Advanced Wound Management | $5.55B | $5.21B | $5.21B | - | - |
| Orthopaedics Sports Medicine And Ent And Advanced Wound Management | - | - | - | $4.56B | $5.14B |
| Orthopaedics Sports Medicine And Ear Nose And Throat | - | - | - | $3.25B | $3.76B |
Smith & Nephew's latest annual revenue breakdown by segment (product or service), as of Dec 23: Orthopaedics, Sports Medicine and ENT and Advanced Wound Management (50.00%), Orthopaedics, Sports Medicine and Ear Nose and Throat (35.53%), and Advanced Wound Management (14.47%).
Smith & Nephew Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| United States of America | $2.76B | $2.66B | - | - | - |
| China | $319.00M | $352.00M | - | - | - |
| C | - | - | $318.00M | $336.00M | - |
| U | - | - | $2.34B | $2.55B | $2.35B |
| G | - | - | $166.00M | $211.00M | $211.00M |
Smith & Nephew's latest annual revenue breakdown by geography, as of Dec 22: United States of America (89.65%), and China (10.35%).
Smith & Nephew Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SNN | Smith & Nephew | $5.55B | $2.79B |
| BRKR | Bruker | $2.96B | $800.70M |
| ITGR | Integer | $1.60B | $753.01M |
| GMED | Globus Medical | $1.57B | $629.69M |
| CNMD | CONMED | $1.24B | $332.10M |
| LIVN | LivaNova | $1.15B | $318.60M |
| IRTC | iRhythm | $492.68M | $148.05M |
| ATEC | Alphatec | $482.26M | $42.98M |
| GKOS | Glaukos | $314.71M | $95.69M |
| FNA | Paragon 28 | $216.39M | $61.02M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| CFMS | Conformis | $62.05M | $13.02M |
| MOTS | Motus GI | $319.00K | $64.00K |
| OFIX | Orthofix Medical | $100.00K | $198.62M |
SNN Revenue FAQ
What is Smith & Nephew’s yearly revenue?
Smith & Nephew's yearly revenue for 2023 was $5.55B, representing an increase of 6.40% compared to 2022. The company's yearly revenue for 2022 was $5.22B, representing an increase of 0.06% compared to 2021. SNN's yearly revenue for 2021 was $5.21B, representing an increase of 14.30% compared to 2020.
What is Smith & Nephew’s quarterly revenue?
Smith & Nephew's quarterly revenue for Q4 2023 was $2.79B, a 2.14% increase from the previous quarter (Q2 2023), and a 113.59% increase year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $2.73B, a 100.00% increase from the previous quarter (Q1 2023), and a 5.15% increase year-over-year (Q2 2022). SNN's quarterly revenue for Q1 2023 was $1.37B, a -50.16% decrease from the previous quarter (Q4 2022), and a 5.15% increase year-over-year (Q1 2022).
What is Smith & Nephew’s revenue growth rate?
Smith & Nephew's revenue growth rate for the last 3 years (2021-2023) was 6.47%, and for the last 5 years (2019-2023) was 8.00%.
What are Smith & Nephew’s revenue streams?
Smith & Nephew's revenue streams in c 23 are Advanced Wound Management, Orthopaedics, Sports Medicine and Ear Nose and Throat, and Orthopaedics, Sports Medicine and ENT and Advanced Wound Management. Advanced Wound Management generated $1.61B in revenue, accounting 14.47% of the company's total revenue, up 6.22% year-over-year. Orthopaedics, Sports Medicine and Ear Nose and Throat generated $3.94B in revenue, accounting 35.53% of the company's total revenue, up 6.48% year-over-year. Orthopaedics, Sports Medicine and ENT and Advanced Wound Management generated $5.55B in revenue, accounting 50.00% of the company's total revenue, up 6.40% year-over-year.
What is Smith & Nephew’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Smith & Nephew was Orthopaedics, Sports Medicine and ENT and Advanced Wound Management. This segment made a revenue of $5.55B, representing 50.00% of the company's total revenue.